Finance

Beta
Lists
MLLCF:OTCMKTS
Molecular Partners AG
$4.85
0.00%
(0.00) 1D
May 28, 10:13:21 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MLLCF...
Mkt. cap
158.33M
Avg. vol.
17.00
Volume
0.00
52-wk high
$4.15
52-wk low
$2.25
Beta
-31.17
Shares outstanding
40.38M
No. of employees
134
Mkt. cap
158.33M
Avg. vol.
17.00
Volume
0.00
52-wk high
$4.15
52-wk low
$2.25
Beta
-31.17
Shares outstanding
40.38M
No. of employees
134
News stories
From sources across the web
Profile
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
About Molecular Partners AG
CEO-
Employees134
Founded2004
Headquarters-
SectorBiotechnology
Websitemolecularpartners.com
Previous reportsAll values in CHF
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CHF
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
10.71M
8.33M
8.18M
9.44M
Cost of revenue
10.71M
8.33M
8.18M
9.44M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.99M
3.60M
4.48M
4.00M
Operating expense
3.99M
3.60M
4.48M
4.00M
Total operating expenses
14.70M
11.93M
12.67M
13.44M
Operating income
-14.70M
-11.93M
-12.67M
-13.44M
Other non operating income
-3.00K
-2.00K
-5.00K
-4.00K
EBT including unusual items
-20.40M
-11.84M
-12.64M
-13.14M
EBT excluding unusual items
-17.78M
-11.72M
-12.69M
-13.14M
Income tax expense
-
-
4.00K
-
Effective tax rate
-
-
-0.03%
-
Other operating expenses
-
-
-
-
Net income
-20.40M
-11.84M
-12.65M
-13.14M
Net profit margin
-
-
-
-
Earnings per share
-0.56
-0.33
-0.36
-0.35
Interest and investment income
420.00K
366.00K
234.00K
176.00K
Interest expense
-4.00K
-3.00K
-6.00K
-7.00K
Net interest expenses
416.00K
363.00K
228.00K
169.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.15M
-11.40M
-12.44M
-12.94M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer